Incyte (INCY) PT Lowered to $144 at BMO Capital
Tweet
Share
E-mail
Get Alerts INCY Hot Sheet
Price: $123.22 --0%
Rating Summary:
18 Buy, 17 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 33
Rating Summary:
18 Buy, 17 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 33
Join SI Premium – FREE
BMO Capital lowered its price target on Incyte (NASDAQ: INCY) to $144.00 (from $170.00) while maintaining a Outperform rating.
Analyst M. Ian Somaiya pushes out US launch timelines for baricitinib by 3 years citing the FDA need for additional dosing and safety data noting new trials will need to be done.
Somaiya lowers FY 2017 EPS estimate from $0.51 to $0.24 and lowers FY 2018 EPS estimate from $1.20 to $1.02.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aon Corp (AON) PT Lowered to $360 at BMO Capital
- BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $90; Piper Sandler: 'Remain Buyers'
- Kepler Cheuvreux Upgrades Entain PLC (ENT:LN) (GMVHF) to Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT ChangeRelated Entities
BMO Capital, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
